The Drug-Induced Respiratory Disease Website
Philippe Camus, M.D.
Browse by »
Pulmonary arterial hypertension
Will reverse in some patients upon drug discontinuance
Last update :
No medias available.
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
American journal of hematology 2015;; 2015
Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition.
The European respiratory journal 2013;42;869-70 2013
Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
BMJ case reports 2014;2014; 2014
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2011;38;218-20 2011
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
BMC pulmonary medicine 2011;11;30 2011
Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?
Leukemia research 2012;36;813-4 2012
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib.
Circulation 2012;; 2012
Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
Internal medicine (Tokyo, Japan) 2012;51;2337-40 2012
Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.
Herz 2013;; 2013
Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient.
Bone marrow transplantation 2009;43;967-8 2009
Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
Leukemia research 2012;36;e4-6 2012